Inappropriate requests for serum anti-epileptic drug levels in hospital practice

QJM: An International Journal of Medicine

Volumn 97, Issue 6, 2004, Pages 337-341

  Walters, R J L ^a   Hutchings, A D ^b   Smith, D F ^c   Smith, P E M ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DIPLOPIA; DOSE RESPONSE; DRUG BLOOD LEVEL; EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOXICITY TESTING; UNITED KINGDOM;

EID: 3042589235     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hch057     Document Type: Article

References (12)

1. Scottish Intercollegiate Guidelines Network (SIGN) Guideline no. 70. Diagnosis and management of epilepsy in adults. [http://www.sign.ac.uk/pdf/sign70.pdf] Accessed 25 April 2004.
2. Buchthal F, Svensmark O. Aspects of pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia 1960; 1:373-84.
3. Thomson AH, Brodie MJ. Pharmacokinetic optimisation of anticonvulsant therapy. Clin Pharmacokinet 1993; 24:441-52.
4. Richens A, Dunlop A. Serum phenytoin levels in the management of epilepsy. Lancet 1975; 2:247-9.
5. Chadwick D. Overuse of monitoring blood concentrations of antiepileptic drugs. Br Med J 1987; 294:723-4.
6. Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. Arch Neurol 1974; 31:289-94.
7. Turnbull DM, Howel D, Rawlins MD, Chadwick DW. Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J 1985; 290:815-19.
8. Gannaway DJ, Mawer GE. Serum phenytoin concentrations and clinical response in patients with epilepsy. Br J Clin Pharmacol 1981; 12:833-9.
9. Maloney TW, Rogers DE. Medical technology - a different view of the contentious debate over costs. N Engl J Med 1979; 301:1413-19.
10. Schoenenberger RA, Tanasijevic MJ, Jha J, Bates DW. Appropriateness of anti-epileptic drug level monitoring. JAMA 1995; 274:1622-6.
11. Richens A, Perucca E. Clinical pharmacology and medical treatment. In: Laidlaw J, Richens A, Chadwick DW, eds. A textbook of epilepsy, 4th edn. New York, Churchill Livingstone, 1992:535-40.
12. Pearce GA, Day DO. Compliance with criteria necessary for effective drug concentration monitoring. Ther Drug Monit 1990; 12:250-7.